Cargando…
The application of anticoagulant therapy to sepsis
Since the withdrawal of recombinant-activated protein C, the anticoagulant therapy for sepsis was taken no notice. For instance, the international sepsis guidelines did not share a space for this therapy. However, we can see the signs of change recently. The Surviving Sepsis Campaign Guidelines 2016...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450244/ https://www.ncbi.nlm.nih.gov/pubmed/28572981 http://dx.doi.org/10.1186/s40560-017-0230-3 |
_version_ | 1783239930547273728 |
---|---|
author | Thachil, Jecko Iba, Toshiaki |
author_facet | Thachil, Jecko Iba, Toshiaki |
author_sort | Thachil, Jecko |
collection | PubMed |
description | Since the withdrawal of recombinant-activated protein C, the anticoagulant therapy for sepsis was taken no notice. For instance, the international sepsis guidelines did not share a space for this therapy. However, we can see the signs of change recently. The Surviving Sepsis Campaign Guidelines 2016 introduced the development of recombinant thrombomodulin, and the European Society of Intensive Care Medicine released comments on this subject. However, since small but important discrepancy was recognized between the standpoints of Japan (more aggressive) and other countries (rather conservative), we intend to discuss on this point. |
format | Online Article Text |
id | pubmed-5450244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54502442017-06-01 The application of anticoagulant therapy to sepsis Thachil, Jecko Iba, Toshiaki J Intensive Care Letter to the Editor Since the withdrawal of recombinant-activated protein C, the anticoagulant therapy for sepsis was taken no notice. For instance, the international sepsis guidelines did not share a space for this therapy. However, we can see the signs of change recently. The Surviving Sepsis Campaign Guidelines 2016 introduced the development of recombinant thrombomodulin, and the European Society of Intensive Care Medicine released comments on this subject. However, since small but important discrepancy was recognized between the standpoints of Japan (more aggressive) and other countries (rather conservative), we intend to discuss on this point. BioMed Central 2017-05-30 /pmc/articles/PMC5450244/ /pubmed/28572981 http://dx.doi.org/10.1186/s40560-017-0230-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Letter to the Editor Thachil, Jecko Iba, Toshiaki The application of anticoagulant therapy to sepsis |
title | The application of anticoagulant therapy to sepsis |
title_full | The application of anticoagulant therapy to sepsis |
title_fullStr | The application of anticoagulant therapy to sepsis |
title_full_unstemmed | The application of anticoagulant therapy to sepsis |
title_short | The application of anticoagulant therapy to sepsis |
title_sort | application of anticoagulant therapy to sepsis |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450244/ https://www.ncbi.nlm.nih.gov/pubmed/28572981 http://dx.doi.org/10.1186/s40560-017-0230-3 |
work_keys_str_mv | AT thachiljecko theapplicationofanticoagulanttherapytosepsis AT ibatoshiaki theapplicationofanticoagulanttherapytosepsis AT thachiljecko applicationofanticoagulanttherapytosepsis AT ibatoshiaki applicationofanticoagulanttherapytosepsis |